Search Results
Jul 28, 2026, 13:23 ET Next Level Solutions Selected by Safepoint MGA to Deliver New Customer Self-Service Portal
SolutionsNext Level Solutions (NLS) is a technology consulting and systems integration firm focused on the property and casualty insurance industry. Headquartered in Springfield, Missouri, with nearshore delivery hubs in Puerto Rico and Honduras, NLS helps carriers implement, stabilize, and
More news about: Next Level Solutions
May 28, 2026, 06:00 ET Braille Institute Invites Readers Everywhere to Join Free Nationwide Summer Reading Program Featuring Bestselling Authors, National Parks, and Immersive Storytelling
/PRNewswire/ -- Braille Institute Library is proud to announce that it has been selected by the National Library Service for the Blind and Print Disabled (NLS), Library of Congress, to curate and host the 2026 Adult Summer Reading Program, a nationwide nine-week literary and learning experience designed for
More news about: Braille Institute of America
Apr 09, 2026, 13:30 ET Schréder Announces Acquisition of NLS Lighting
highest standards of performance, durability, and visual comfort across a wide range of outdoor environments. NLS is widely recognized for its exceptional lead times and service levels.NLS Lighting's portfolio spans a comprehensive range of outdoor lighting solutions, including area, site, architectural
More news about: Schréder USA
Feb 19, 2026, 15:22 ET Two Male Birth Control Options Advance Into Phase II Clinical Trials
contraceptive solution for men and couples interested in on-demand solutions with NLS-133, a non-hormonal male contraceptive pill, designed to provide 24 hours of protection and for use as either an on-demand or daily pill. NLS-133 has begun a Phase II clinical trial where participants' semen levels are
More news about: NEXT Life Sciences, Inc.
Dec 02, 2025, 17:31 ET Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options | DelveInsight
rapid onset, and low abuse potential. The ongoing Phase III AMAZE trials (NLS-1031, NLS-1032) are assessing its effect on weekly cataplexy frequency, followed by a 12-month open-label extension. Leveraging this clinical evidence, NLS Pharmaceutics intends to file a new drug application (NDA) for QUILIENCE
More news about: DelveInsight Business Research, LLP
Nov 06, 2025, 07:00 ET NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
platforms following the merger of Kadimastem and NLS Pharmaceutics and its ability to deliver meaningful therapeutic advances for patients worldwide. These forward-looking statements and their implications are based on the current expectations of the management of NLS and Kadimastem and are subject to a number
More news about: NewcelX Ltd.
Nov 04, 2025, 07:00 ET NewcelX CEO Issues Letter to Shareholders
Financial Strength and Strategic Outlook The merger between NLS Pharmaceutics Ltd. ("NLS") and Kadimastem Ltd. ("Kadimastem") established NewcelX Ltd., a biotechnology company that combines Kadimastem's advanced cell-therapy platforms
More news about: NewcelX Ltd.
Nov 03, 2025, 08:25 ET NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.
content:https://www.prnewswire.com/news-releases/newcelx-provides-business-and-strategic-roadmap-update-following-closing-of-merger-with-nls-pharmaceutics-ltd-302602565.html
More news about: NewcelX Ltd.
Oct 30, 2025, 16:15 ET NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
Reorganization, as amended from time to time, dated as of November 4, 2024 (the "Merger Agreement"), by and among NewcelX (f/k/a NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS")), NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. ("Kadimastem"), effective as of October 30, 2025 (the "Merger"). Upon
More news about: NewCelX Ltd.; NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 30, 2025, 07:00 ET NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
About NLS Pharmaceutics Ltd. NLS Pharmaceutics (Nasdaq: NLSP) is a Swiss biopharmaceutical company developing therapies for CNS and neurodegenerative disorders. Following its merger with Kadimastem Ltd., NLS will operate as NewCelX Ltd.,
More news about: NLS Pharmaceutics Ltd.
Oct 29, 2025, 07:00 ET NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 29, 2025, 06:00 ET NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 29, 2025, 03:53 ET NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd.
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 27, 2025, 07:00 ET NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 23, 2025, 06:01 ET NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
extraordinary general meeting of NLS dated September 29, 2025 (the "EGM"). Based on the Exchange Ratio, each ordinary Kadimastem share will be exchanged for approximately 6.92 NLS ordinary shares prior to the reverse stock split, which was approved by NLS shareholders at the EGM, or
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 17, 2025, 03:00 ET SIMAGIC at SimRacing Expo 2025: A Triple Reveal
Super GT (Steve) — Known globally for his blend of humor, high-level racing, and real-world competition in the Nürburgring Langstrecken-Serie (NLS), he brings unique insights into the connection between simulation and motorsport. Jackzer
More news about: SIMAGIC TECHNOLOGY CO., LIMITED
Oct 17, 2025, 03:00 ET SIMAGIC auf SimRacing Expo 2025: Eine Dreifach-Enthüllung
GT (Steve) – Weltweit bekannt für seine Mischung aus Humor, hochkarätigem Rennsport und realem Wettbewerb in der Nürburgring-Langstrecken-Serie (NLS), bietet er einzigartige Einblicke in die Verbindung zwischen Simulation und Motorsport. Jackzer
More news about: SIMAGIC TECHNOLOGY CO., LIMITED
Oct 17, 2025, 03:00 ET SIMAGIC at SimRacing Expo 2025: A Triple Reveal
Super GT (Steve) — Known globally for his blend of humor, high-level racing, and real-world competition in the Nürburgring Langstrecken-Serie (NLS), he brings unique insights into the connection between simulation and motorsport. Jackzer
More news about: SIMAGIC TECHNOLOGY CO., LIMITED
Oct 17, 2025, 03:00 ET SIMAGIC à SimRacing Expo 2025 : une triple révélation
(Steve) - Connu dans le monde entier pour son mélange d'humour, de course de haut niveau et de compétition réelle dans la Nürburgring Langstrecken-Serie (NLS), il apporte un éclairage unique sur le lien entre la simulation et le sport automobile. Jackzer
More news about: SIMAGIC TECHNOLOGY CO., LIMITED
Oct 17, 2025, 03:00 ET SIMAGIC en SimRacing Expo 2025: Triple revelación
(Steve) — Conocido mundialmente por su mezcla de humor, carreras de alto nivel y competencia en el mundo real en la Nürburgring Langstrecken-Serie (NLS), aporta conocimientos únicos sobre la conexión entre la simulación y el deporte del motor.
More news about: SIMAGIC TECHNOLOGY CO., LIMITED
Oct 13, 2025, 10:05 ET FADEL Unveils Next Chapter in AI Innovation with Agentic Automation on AWS Bedrock
AI-Powered Business Insights: Natural Language Search (NLS) through AI prompts, predictive analytics, dynamic dashboards, and instant executive reports that convert complex licensing data into actionable insights.
More news about: FADEL
Sep 30, 2025, 08:01 ET Duck Creek Technologies Announces 2025 Partner of the Year Award Winners
and exceeds delivery adherence standards. Next Level Solutions (NLS) has also built a robust FY26 pipeline, set to drive significant new revenue and accelerate expansion across key market segments. Beyond their implementation excellence, NLS has demonstrated outstanding commitment to professional development
More news about: Duck Creek Technologies, Inc.
Sep 30, 2025, 07:00 ET NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Sept. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Sep 10, 2025, 06:00 ET Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
Solicitation NLS, Kadimastem, and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from NLS and Kadimastem shareholders in respect of the proposed transaction. Information about the directors and executive officers of NLS, including
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.